beyond pink team
  • Home
  • About Us
    • Who We Are
    • Our Board
    • Annual Report
    • Contact Us
  • Support
    • Physical
    • Emotional
    • Community
    • Financial
    • Caregiver
    • Online
  • Education
    • Newsletter
    • Ignite the Cancer Conversation
    • Quality Care
    • Resources
    • Request Speaker
    • The Cancer Journey
  • Advocacy
    • What is Advocacy
    • National Breast Cancer Coalition
    • Iowa Stop Breast Cancer
    • Research
    • Influencing Policy
    • Access to Care
  • Join Us
    • Be an Advocate
    • Volunteer
    • Events >
      • 16th Annual Pink Ribbon Run
    • Membership
    • Donate to BPT
    • Follow Us
 If you are Breast Cancer Survivor and  you would like to contribute your story to our Newsletter, 
​please send us a message here.
DOWNLOAD Current NewsletteR

Categories

All
Advocacy
Bone Health
Breast Density
Breast Disease
Caregivers
COVID 19
COVID-19
Emotional Support
Environment
Exercise
Fatigue
Financial
Gender
Genetic Testing
Grief
High Risk
Hormone Replacement Therapy
Ignite
Implants
Intimacy After Cancer
LGBTQ
Lymphedema
Mammography
Meditation
Men
Mental Health
Metastasis
MRI
NBCC
Nutrition
Obesity
Pain
Pregnancy
Prevention
Radiation
Reconstruction
Reduce Risk
Rehabilitation
Screening
Sex
Side Effects
Support Groups
Surgery
Survivor
Survivorship
Treatment
Vaccine
Yoga
Young Women

Archives

January 2023
October 2022
July 2022
April 2022
January 2022
October 2021
July 2021
April 2021
January 2021
October 2020
July 2020
April 2020
January 2020
October 2019
July 2019
April 2019
January 2019
October 2018
July 2018
April 2018
January 2018
October 2017
July 2017
April 2017
January 2017
October 2016
July 2016
April 2016
January 2016
October 2015
July 2015
April 2015
January 2015
October 2014
July 2014
April 2014
January 2014
October 2013
July 2013
April 2013
January 2013
October 2012
July 2012
April 2012
January 2012
October 2011
July 2011
April 2011
January 2011
October 2010
July 2010
April 2010
January 2010
October 2009
July 2009
April 2009
January 2009
October 2008
July 2008
April 2008
January 2008
October 2007
July 2007
April 2007
January 2007
October 2006
July 2006
April 2006
January 2006
October 2005
July 2005
April 2005
January 2005
October 2004
July 2004
April 2004
January 2004

HER-2/NEU TESTING AND HERCEPTIN

1/1/2006

0 Comments

 

Picture
by Dr. Joginder Singh, M.D.

About 200,000 women are diagnosed with breast cancer each year in the United States and 40,000 women die each year due to this disease. There are different factors which determine the chances for recurrence after primary surgery (of mastectomy or lumpectomy and radiation therapy) and different factors which determine survival of patients who have metastatic breast cancer.

It’s known that tumor characteristics such as estrogen and progesterone receptors, as well as grading of the tumor, determine the prognosis in women with breast cancer. However, clinicians have been surprised many times that some women with large tumors and many positive lymph nodes have no recurrence while other women with only small tumors have recurrences. Similarly, in patients with metastatic breast cancer (breast cancer spread to other organs) it is known that women with disease only in the bones live longer than women who have disease in the lungs, liver and brain. However, there are exceptions to the rule.

The clinicians and scientists have been studying women with small tumors who had recurrences and a subset of metastatic breast cancer patients who have a rapid progression of disease to determine why some patients have aggressive cancers and others do not. One of the genes that was found to be of prognostic value, and later found to be useful for treatment, is HER2/NEU.

HER-2/NEU is a gene that helps control how the cells grow, divide and repair themselves. About 30% of breast cancers have too many copies of the HER-2/NEU gene. The HER-2/NEU gene directs the production of special proteins, called HER-2 receptors, on the cells.

​Cancer with too many copies of HER-2 or too many HER-2 receptors tends to grow fast and are associated with an increased risk of spread. They do respond very well to the treatment that works against HER-2/NEU. This targeted therapy is called Herceptin. It works specifically by binding to HER2/NEU positive cancer cells and killing them.

There are two tests for HER2/NEU:
IHC Test (ImmunoHistoChemistry)
The IHC test shows if there are too many HER-2 receptor proteins in the cancer cells. The results of the IHC test can be zero (negative), 1+ ​(negative), 2+ (borderline) or 3+ (positive).

FISH Test (Fluorescent In Situ Hybridization)
The FISH test shows if there are too many copies of HER-2/NEU gene in the cancer cells. The results of the FISH test can be positive (extra copies) or negative (normal number of copies) Finding out which HER-2/NEU test was done is important. Only cancers that have 3+ or FISH positive will respond well to therapy that works against HER2/NEU. If you have 2+ test results on immunohistochemistry, the test result is borderline. Some patients respond to Herceptin and others do not. If the results by immunohistochemistry are 2+ you should ask to have the tissue tested by FISH test. The results by FISH test are more accurate and determine whether the tumor will respond to Herceptin or not. The FISH test is the preferred method for testing at this time.

HERCEPTIN IN METASTATIC BREAST CANCER
Herceptin alone
The studies of patients with HER2/NEU positive breast cancers given Herceptin as a single agent showed 14% of the women’s tumors were resistant to chemotherapy. This was a significant result, especially since metastatic breast cancer, which is HER-2/NEU positive, tends to be aggressive.

Herceptin with chemotherapy
In other studies, women with breast cancer got even better results when they took Herceptin together with chemotherapy drugs. Herceptin has been studied with many drugs including Taxol, Adriamycin (doxorubicin) and Navelbine. The combination of Herceptin and chemotherapy also improved survival in women with metastatic breast cancer. A small number of women who took Adriamycin and Herceptin had significant heart problems, including congestive heart failure. This is a condition in which the heart is unable to pump effectively. At this time, Herceptin along with Adriamycin should be avoided.

Herceptin in adjuvant treatment of breast cancer
Adjuvant treatment is a treatment given to women whose cancers have been removed by surgery. The purpose of adjuvant treatment is to prevent recurrences of the breast cancer in other organs of the body. In recent trials, 3,300 women with early stage breast cancer, whose tumors were removed by surgery, were given adjuvant treatment with a combination of Herceptin and chemotherapy or chemotherapy alone. Patients showed a 52% decrease in disease recurrence when Herceptin was given with chemotherapy compared with chemotherapy alone.

​This is a major advance for thousands of women with breast cancer. These results are examples that we are at a major turning point in the use of targeted therapies to eliminate suffering and death from cancer. Herceptin, however, is not for everybody. Patients with breast cancer, which do not have HER2/NEU expression, do not respond or benefit from Herceptin.

Heart failure
One of the most fearful side effects of Herceptin is heart failure and this poses a dilemma for patients who have a small chance for recurrence. In these patients, the benefit from adding Herceptin to chemotherapy or Herceptin therapy alone, is small. Patients on Herceptin therapy should be monitored regularly even though the chance of heart failure is low (up to 4.1%). Anytime there is evidence that Herceptin is causing a decrease in the pumping force of the heart (ejection fraction), Herceptin should be stopped. 

Picture
Read Full Newsletter
0 Comments



Leave a Reply.

CONTACT US

Beyond Pink TEAM
c/o Jeanne Olson, Treasurer
1407 Asbury Lane
Waterloo, IA 50701
​beyondpinkteam@gmail.com
(319) 239-3706
©2020 Beyond Pink TEAM
  • Home
  • About Us
    • Who We Are
    • Our Board
    • Annual Report
    • Contact Us
  • Support
    • Physical
    • Emotional
    • Community
    • Financial
    • Caregiver
    • Online
  • Education
    • Newsletter
    • Ignite the Cancer Conversation
    • Quality Care
    • Resources
    • Request Speaker
    • The Cancer Journey
  • Advocacy
    • What is Advocacy
    • National Breast Cancer Coalition
    • Iowa Stop Breast Cancer
    • Research
    • Influencing Policy
    • Access to Care
  • Join Us
    • Be an Advocate
    • Volunteer
    • Events >
      • 16th Annual Pink Ribbon Run
    • Membership
    • Donate to BPT
    • Follow Us